Marihuana Abuse Treatment Study

Download Report

Transcript Marihuana Abuse Treatment Study

MTP Marijuana Treatment Project

The Multi-site Study of the Effectiveness of Brief Treatment for Cannabis Dependence A Cooperative Agreement funded by SAMHSA-CSAT

Primary Research Questions

 Are brief treatments more effective than deferred treatment (referral to a waiting list control group)?

 Does a 9 session treatment produce better outcomes than a 2 session treatment?

 Do these treatments vary in effectiveness in diverse population groups in relation to gender, ethnicity, and employment status?

Rationale for a Multi-site Trial

Marijuana is the most commonly abused illicit substance in the U.S.

Large numbers of chronic users have developed cannabis dependence

Previous small-scale clinical trials have demonstrated the efficacy of brief and extended treatments

Further research is needed to test the robustness of effect and its generalizability to broad populations

MTP Collaborating Sites

Sponsoring Agency

Substance Abuse and Mental Health Services Administration/ Center for Substance Abuse Treatment

Coordinating Center

University of Connecticut, School of Medicine, Farmington, CT

Yale University, New Haven, CT

Clinical Research Units

University of Washington, Seattle, WA

University of Connecticut, School of Medicine, Farmington, CT

The Village, Inc., Miami, FL

Experimental Groups

Brief Treatment Group (N=146)

2 sessions of Motivational Enhancement Therapy

Delivered over a 5-week period

Extended Treatment Group (N=156)

9 sessions: 2 of Motivational Enhancement Therapy, 5 of Cognitive Behavioral Therapy, and 2 of Clinical Case Management

Delivered over a 12-week period

Delayed Treatment Control Group (N=148)

Treatment initiation scheduled 4 months after date of study enrollment

Choice of brief or extended treatment at end of delay period

Study Design

Recrutiment of 450 chronic marijuana users through advertising and referral Screening for Eligibility Enrollment and Informed Consent Baseline Assessment Random Assignment Delayed Treatment Control (DTC) Brief Treatment (BT) Follow-up Evaluation 4, 9, and 15 months Extended Treatment (ET)

Overview of the Cognitive Study

Purpose

To evaluate the effects of short-term (4-months) abstinence on recovery of cognitive functioning

Design

Cognitive assessment battery administered to DTC volunteers at beginning and end of treatment

Treatment responders (abstainers) will be compared with clients who continue to use MJ

Assessment Procedures & Variables

MTP Screening Questionnaire

Demographics

Current alcohol and drug use

Lifetime dependence history

Medical and psychiatric history

Structured Clinical Interview for DSM-IV

DSM-IV criteria for alcohol and drug abuse and marijuana dependence

Assessment Procedures & Variables

 Time Line Follow-Back Interview 

Weekly summary data for frequency of marijuana, alcohol and other drug use for ‘past 90 days’

Summary of quantity of marijuana, alcohol, cigarette use for ‘past 90 days'

Hazardous use of marijuana for ‘past 90 days’

 Addiction Severity Index 

Lifetime & current alcohol and drug history

Medical history

Employment and support status

Legal history

Psychiatric history

Assessment Procedures & Variables

Self Report Questionnaires

Beck Depression Inventory

Self Efficacy Questionnaire

Reasons for Quitting

Marijuana Problem Scale

Readiness to Change Questionnaire

Coping Strategies Scales

Ambivalence Measure

State-Trait Anxiety Inventory

Urinalysis

10 Psychoactive Substances

Inclusion/Exclusion Criteria

 Meets DSM-IV Diagnosis for Cannabis Dependence  Has smoked cannabis on at least 40 of the last 90 days  Does not meet DSM-IV dependence criteria for other drugs or alcohol  Is not involved in concurrent therapy or 12-step meetings  Does not have a medical or psychiatric diagnosis that would interfere with treatment

Inclusion/Exclusion Criteria, cont.

 Is within 60 miles of clinic  Is able to name one person to serve as a locator  Has legal status that allows involvement in the protocol  Is not subject to mandatory urine screens  Is at least 18 years old  Has the ability to speak and understand English

Demographic Characteristics of MTP Participants (N=450) Characteristic Mean Age Sex Male Female Ethnicity European American African American Hispanic American Other 36 68% 32% 69% 17% 12% 02%

Demographic Characteristics of MTP Participants, cont. (N=450) Characteristic Marital Status Not Married Married/Cohabiting Mean Years Education Employed Full Time Part Time Unemployed Student/Retired/Homemaker Mean Number Years/Present Job 60% 40% 14 69% 14% 12% 05% 5

Marijuana Use Characteristics at Baseline (N=450) Characteristic Number of Years of Regular Marijuana Use Number of Years of Problem Marijuana Use Number of Endorsed Marijuana Dependence Symptoms (of 7) Number of Endorsed Marijuana Related Problems (of 19) Mean (SD) 17.94

(7.73) 8.92

(7.64) 5.36

(1.26) 9.38

(3.55)

Marijuana Dependence Symptoms Endorsed at Baseline (N=450) Symptom MJ taken in larger amounts or over a longer period than intended Persistent desire or one or more unsuccessful attempts to cut down or control use A great deal of time spent in activities necessary to get, use, or recover from the effects of MJ Important social, occupational or recreational activities given up because of MJ use 77% 96% 83% 64%

Marijuana Dependence Symptoms Endorsed at Baseline, cont. (N=450) Symptom Continued use despite knowledge of a psychological or physical problem caused or exacerbated by MJ use The need for markedly increased amounts of MJ to achieve the desired effect (tolerance) Experienced withdrawal

Appetite disturbance

   

Sleep disturbance Night sweats Headaches Irritability 95% 68% 78%

Marijuana Related Problems Endorsed at Baseline (N=450) Marijuana Related Problems Feeling bad about marijuana use To have lower energy level To procrastinate Memory loss To have lower productivity Lowered self-esteem To lack self confidence 90% 86% 86% 76% 75% 74% 68%

Marijuana Related Problems Endorsed at Baseline, cont. (N=450) Marijuana Related Problems Problems between you and your partner Financial difficulties Difficulty sleeping Problems with your family To neglect your family Medical problems Problems between you and your friends 58% 49% 46% 44% 38% 34% 26%

Lifetime Treatment History Reported at Baseline (N=450) % Number of Times Treated in Lifetime Drug Abuse 0 1 2 3 or > Alcohol Abuse 0 1 2 82% 12% 2% 4% 93% 4% 3% Mean (SD) .31

(.94) .17

(.96)

Number of Days of Marijuana Use in the Past 90 Days - Baseline (N=450)

Mean = 80.0

SD = 14.6

200 175 150 125 100 75 50 25 0 25.0

30.0

35.0

40.0

45.0

50.0

55.0

60.0

65.0

70.0

75.0

80.0

85.0

90.0

Number of Days Smoked Marijuana in the Past 90 Days

Number of Joints Smoked Per Day in the Past 90 Days - Baseline (N=450)

Mean = 2.9

SD = 2.3

200 175 150 125 100 75 50 25 0 0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

18.0

Number of Joints Smoked per Day in Last 90 Days

Number of Hours High Per Day in the Past 90 Days - Baseline (N=450)

Mean = 6.6

SD = 4.6

175 150 125 100 75 50 25 0 0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

22.5

25.0

Number of Hours Felt High in the Past 90 Days

Number of Marijuana Dependence Symptoms Endorsed in the Past 90 Days - Baseline (N=450)

Mean = 5.6

SD = 1.3

160 140 120 100 80 60 40 20 0 2.0

3.0

4.0

5.0

6.0

7.0

Number of Marijuana Dependence Symptoms Endorsed

Number of Marijuana Related Problems Endorsed on the MPS - Baseline (N=450)

Mean = 9.6

SD.= 3.6

160 140 120 100 80 60 40 20 0 0.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

20.0

Number of Marijuana-Related Problems (of 19)

Marijuana Use Within 1 Hour Prior to Driving in the Past 90 Days - Baseline (N=450)

60 50 40 30 20 10 0 Neve r Less t han Week ly Week ly Daily /Almost D aily Less t han Daily Marijuana Used Within 1 Hour Prior to Driving

Marijuana Use Within One Hour Prior to Working on a Paid Job in the Past 90 Days - Baseline (N=373)

50 40 30 20 10 0 Neve r Less t han Week ly Week ly Daily /Almost D aily Less t han Daily Marijuana Used Within 1 Hour Prior to Working

MTP Treatment Attendance (N=450)

6

Number of Sessions 7 8 9 0 1 2 3 4 5 6 Mean Sessions Attended (SD) % Brief 6.8

21.2

71.9

1.65

(.61) % Extended 8.3

7.1

6.4

7.1

5.1

5.1

4.5

4.5

9.6

42.3

6.03

(3.31)

MTP Follow-up Rates

Post Treatment Follow-up Rate 4-Month Rates: Follow-up Collateral Urine 9-Month Rates: Follow-up Collateral Urine 15-Month Follow-up Rate 21-Month Follow-up Rate 88% 89% 100% 86% 87% 100% 81% 82% 77%

Participants Lost to 4-month Follow-up

Variable % Treatment Assign BT DTC ET % Sex Male Female % Ethnic White Black Hispanic Followed Participants (N=398) 32.2

34.4

33.4

Follow-up Drop-outs (N=52) 34.6

21.2

44.2

67.8

32.2

73.1

26.9

72.1

12.7

15.2

54.9

9.8

35.3

X 2

NS NS 12.58***

Participants Lost to 4-month Follow-up, cont.

Variable Mean Marijuana Severity Score Proportion of days smoked (of last 90 at baseline) Followed Participants (N=398) Follow-up Drop-outs (N=52) 9.57

9.75

88 89 Education Age 14.2

36.3

14.3

34.4

t

NS NS NS NS

Treatment by Time (Baseline, Week 1- Week 16) % of days smoked marijuana per week (N=398) 1 0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

BL W k2 W k4 W k6 W k8 W k10 W k12 W k14 W k16 DTC BT ET

Treatment by Time (BL, Wk1, Wk5, Wk12, Wk16) % of days smoked marijuana per week (N=398) 1 0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

BL 1st Tx End BT End ET 4-Mo F/up DTC BT ET

Intention to Treat Analysis (N=450)

Treatment by Time (BL, Wk1, Wk5, Wk12, Wk16) % of days smoked marijuana per week 1 0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

BL 1st Tx End BT End ET 4-Mo F/up DTC BT ET

Treatment by Time (Baseline, 4-Month Follow-up) SCID Dependence Symptoms (N=398) 7 6 5 4 3 2 1 0 Baseline 4-Month DTC BT ET

Treatment by Time (Baseline, 4-Month Follow-up) Marijuana Problem Scale (N=398) 11 10 9 8 7 6 5 Baseline 4-Month BT DTC ET

Products and Anticipated Accomplishments of MTP

 New findings on the clinical characteristics of chronic marijuana users  New findings on the effectiveness of brief treatments of marijuana dependence  New assessment instruments  New treatment interventions  Treatment manuals for therapists and primary care practitioners  Edited volume of scholarly papers

Research Implications

Development and validation of screening tests and referral procedures

Evaluation of primary care applications of MET brief intervention

Evaluation of brief and extended treatments in CD/behavioral health provider network outpatient settings in terms of

Implementation

Effectiveness

Cost-effectiveness

Unfinished Business

 Cost effectiveness study  Training package covering:  Assessment  Diagnosis  Therapist skills  System issues  Long-term outcome evaluation